AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01403363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: use of fentanyl patch that was halved
Description: A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
Study NCT03644550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: Given intravenous (IV) at recommended phase 2 dose (RP2D) on days 1, 3 and 5 of two (2) 21 day cycles.
Study NCT03644550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravenous (IV) at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.
Study NCT00720811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxycillin
Description: amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
Study NCT00720811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: paracetamol 500mg tablet \<36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
Study NCT05199064 — intervention group
Intervention type: OTHER
Intervention: Ultrasound guided greater occipital nerve (GON) radiofrequency
Description: After identifying the GON with ultrasound guidance, a catheter needle (22-gauge 5 cm 5 mm active tip hybrid electrode) is inserted with an in-plane technique from lateral to medial.After visualizing the electrode tip placed close to the right or left GON, a sensory stimulation test is performed using an RF generator (URF-3AP Diros Tecnology Inc.). After the patient reports dysesthesia and a tingling sensation at the occipital area with less than 0.2 V, the PRF treatment is administered at 5 Hz and 5 milliseconds pulsed width for 360 seconds at 45 V under the constraint that the temperature of the electrode tips does not exceed 42°C
Study NCT00720811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: malaria rapid diagnostic test, respiratory rate timer
Description: malaria dipstick, and breath timer
Study NCT00720811 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Artemether-lumefantrine combination
Description: 20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
Study NCT03983070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seated Rowing Ergometer
Description: Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures
Study NCT03983070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seated Rowing Ergometer
Description: Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures
Study NCT03983070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deadlift
Description: Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.
Study NCT03983070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deadlift
Description: Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.
Study NCT03983070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: An occlusive cuff will be placed around each proximal thigh and inflated to 80% arterial occlusion during exercise sessions.
Study NCT03255590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Configuration task
Description: Training the impaired hand on a configuration task
Study NCT01111487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory positive airway pressure (EPAP) by face mask.
Description: Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
Study NCT03221530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention for Suicide Risk Among Immigrant Youth
Description: The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.
Study NCT03221530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
Study NCT03701945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
Study NCT00241020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study NCT03342846 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: the first group received 20 Hz and the 2nd group received 1 Hz rTMS daily for 10 days 5 sessions every week on M1.
Study NCT01447511 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Control - Warfarin only
Description: A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
Study NCT01953354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO)
Description: Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
Study NCT01953354 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
Study NCT03204747 — intervention group
Intervention type: OTHER
Intervention: Observational study : gait speed
Description: No intervention, only propose water and wait for need to void
Study NCT01447511 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Study NCT01209832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasisulam
Description: Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
Study NCT01209832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
Study NCT03722290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral administration of metformin 250mg (twice a day) for the 1st week followed by metformin 500mg (twice a day) for the next 8 weeks.
Study NCT04763876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Injection 15 mg
Description: A single dose of 15 mg ketorolac administered intramuscularly.
Study NCT04763876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Injection 60 mg
Description: A single dose of 60 mg ketorolac administered intramuscularly.
Study NCT01155479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant 2 mg tablet
Description: Preladenant 2 mg oral tablet taken twice daily
Study NCT01155479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preladenant 5 mg tablet
Description: Preladenant 5 mg oral tablet taken twice daily
Study NCT01155479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg tablet
Description: Preladenant 5 mg oral tablet taken twice daily
Study NCT01155479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant 10 mg tablet
Description: Preladenant 10 mg oral tablet taken twice daily
Study NCT01155479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline 1 mg capsule
Description: Rasagiline 1 mg oral capsule taken once daily
Study NCT01155479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Rasagiline 1 mg capsule
Description: Placebo for rasagiline 1 mg oral capsule taken once daily
Study NCT01155479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Rasagiline 1 mg capsule
Description: Placebo for rasagiline 1 mg oral capsule taken once daily
Study NCT01155479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Preladenant
Description: Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
Study NCT01155479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Preladenant
Description: Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
Study NCT02034136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginsenoside
Description: 3.0 g/ d for 28 days
Study NCT02034136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary fiber fill
Description: 3g/day, 28days
Study NCT00733889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)
Description: Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36
Study NCT00084773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00084773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00084773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00084773 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00353028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate
Description: Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
Study NCT00353028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03566836 — intervention group
Intervention type: DEVICE
Intervention: Garmin Smart Watch
Description: Garmin Smart Watch
Study NCT03566836 — intervention group
Intervention type: DEVICE
Intervention: Garmin Chest Band
Description: Garmin Chest Band
Study NCT01680133 — intervention group
Intervention type: OTHER
Intervention: Hyperinsulinemic euglycemic clamp
Study NCT02577276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele-motion rehabilitation system
Description: Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
Study NCT03630276 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP
Description: Lab
Study NCT02103543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions
Study NCT02103543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar interlaminar epidural steroid injection
Description: single lumbar interlaminar epidural steroid injection
Study NCT02103543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural steroid injection
Description: Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
Study NCT03978208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-346 low dose
Description: Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
Study NCT01447511 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rifampin - Warfarin
Description: A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Study NCT01501448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel and ethinylestradiol
Description: 30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
Study NCT01501448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol valerate
Description: 4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
Study NCT04218435 — intervention group
Intervention type: DRUG
Intervention: Sacubitril / Valsartan Oral Tablet
Description: Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.~Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB.
Study NCT04603703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLAT Manipulation
Description: Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week), HVLAT manipulation/ 1 rep/ 1set/ (3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins.
Study NCT03583242 — intervention group
Intervention type: DRUG
Intervention: Antiangiogenic Agents
Description: 3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
Study NCT03583242 — intervention group
Intervention type: DRUG
Intervention: Corticosteroid
Description: 1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
Study NCT04562337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1316
Description: Anti-PD-L1 antibody
Study NCT04562337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Study NCT01360775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional counseling
Description: Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
Study NCT00590837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1.
Study NCT04562337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Study NCT04562337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Thoracic radiation therapy ,TRT
Study NCT04562337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Study NCT01215630 — intervention group
Intervention type: BEHAVIORAL
Intervention: Aerobic Interval Training
Description: One interval training session
Study NCT04603703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Ultrasound for 10 mins/1 set/ (3 days/ week), Moist hot pack for 10 mins/1 set/ (3 days/ week), Piriformis stretching for 7 sec hold/ 7 repititions/ 1 set/ (3 days/ week), Myofascial release of lumbosacral paraspinal muscles for 3 mins/ 1 set/ (3 days/ week), Gluteal muscles strengthening for 10 sec hold/ 5 reps/ 1 set/ (3 days/ week), Sciatic Neurodynamics with 10 oscillations/ 3 sets/(3 days/ week),~A total of 2 weeks (6 sessions, 3 sessions/ week) were given each consisting of 30 mins.
Study NCT04237415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Study NCT03978208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
Study NCT03978208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-346 mid-dose
Description: Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
Study NCT03978208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-346 standard dose
Description: Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
Study NCT01766843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus and charcoal
Description: 2 inhalations as a single dose
Study NCT01766843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus
Description: 2 inhalations as a single dose
Study NCT01766843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF Easyhaler and charcoal
Description: 2 inhalations as a single dose
Study NCT01766843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF Easyhaler
Description: 2 inhalations as a single dose
Study NCT04057638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Description: Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Study NCT02309710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShangRing
Description: ShangRing administered to males seeking medical male circumcision
Study NCT03946306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5,25% NaOCl with syringe needle irrigation alone
Description: In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
Study NCT03946306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDDY
Description: In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.
Study NCT01519115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early physical therapy intervention
Description: instruction in home care program to be followed for first six weeks after ACF surgery
Study NCT01519115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: one physical therapy visit in hospital following ACF surgery
Study NCT00376688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00376688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT03403972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 250Mg Capsule
Description: Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
Study NCT02862912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: Administered as a single injection or continuously through an indwelling catheter - 50 mg
Study NCT02862912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
Study NCT02862912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups